Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.73 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9131984 | 1.00 | NAAA (0.73) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL10033955 | 1.00 | NAAA (0.73) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL10033782 | 1.00 | NAAA (0.73) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL397795 | 1.00 | NAAA (0.73) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL1695502 | 1.00 | NAAA (0.73) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL9134369 | 1.00 | NAAA (0.73) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL1313739 | 0.98 | NAAA (0.71) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL3291623 | 0.98 | NAAA (0.71) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL4994833 | 0.98 | NAAA (0.71) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL1702458 | 0.98 | NAAA (0.71) | NAAAEPHX1HTTCYP2C19CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542397-B2 | Liquid composition, quantum dot-containing film, optical film, light-emitting display element panel, and light-emitting display device | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-01-03 | — | — | US | disclosed |
| US-20210309866-A1 | LIQUID COMPOSITION, QUANTUM DOT-CONTAINING FILM, OPTICAL FILM, LIGHT-EMITTING DISPLAY ELEMENT PANEL, AND LIGHT-EMITTING DISPLAY DEVICE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2021-10-07 | — | — | US | disclosed |
| EP-3812805-A1 | LIQUID COMPOSITION, QUANTUM DOT-CONTAINING FILM, OPTICAL FILM, LUMINESCENT DISPLAY ELEMENT PANEL, AND LUMINESCENT DISPLAY DEVICE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2021-04-28 | — | — | EP | disclosed |
| CN-112334795-A | Liquid composition, quantum dot-containing film, optical film, light-emitting display element panel, and light-emitting display device | 东京应化工业株式会社 | 2021-02-05 | — | — | CN | disclosed |
| CN-108148153-A | Solid catalyst and prepare the method for acrylic polymers or copolymer using it | 韩华道达尔有限公司 | 2018-06-12 | — | — | CN | disclosed |
| EP-2582453-B1 | TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS | ECOSYNTH NV (BE) | 2016-12-28 | — | — | EP | disclosed |
| US-8865931-B2 | Transesterification process using mixed salt acetylacetonates catalysts | ECOSYNTH BVBA (BE) | 2014-10-21 | — | — | US | disclosed |
| EP-2582453-A2 | TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS | Ecosynth BVBA (BE) | 2013-04-24 | — | — | EP | disclosed |
| US-20130090492-A1 | TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS | ECOSYNTH BVBA (BE) | 2013-04-11 | — | — | US | disclosed |
| WO-2011157645-A2 | TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS | ECOSYNTH BVBA (BE) | 2011-12-22 | — | — | WO | disclosed |
| US-5827863-A | Pyrazole derivatives as angiotensin II antagonists | J. URIACH & CIA, S.A. (ES) | 1998-10-27 | — | — | US | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| WO-1996004273-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA, S.A. (ES) | 1996-02-15 | — | — | WO | disclosed |
| US-4112235-A | Transesterification of carboxylic acids | UOP INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4088820-A | Transesterification of olefins | UOP INC. (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090492-A1 | TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS | ACACA, ACACB, ACSL6 | NAAA 212/4885EPHX1 3576/4885HTT 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.